Lifeloc Reports Second Quarter 2026 Results
Lifeloc reported Q2 2026 revenue of $2.445 million, up 10% year-over-year, with gross margin expanding to 45% from 42%. The net loss narrowed significantly to $(134) thousand, or $(0.05) per diluted share, compared to a net loss of $(394) thousand in the prior year period. The company initiated beta testing for its SpinDetect oral-fluid analyzer and is targeting a limited commercial launch in Q1 2027.
Key figures
- Revenue
- 2444957
- Revenue Yoy
- 10%
- Net loss
- 134000
- Gross margin
- 45%
- Rd investment
- 560000
- Financing amount
- 500000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.